Cliff Asness's CRL Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 265,083 shares of Charles River Laboratories International, Inc. (CRL) worth $39.52 M, representing 0.03% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in CRL, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2017, adding 405,859 shares. Largest reduction occurred in Q2 2020, reducing 631,701 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Charles River Laboratories International (CRL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Charles River Laboratories International (CRL) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +410,101 | Add 0.00% | 410,100 | $37.47 |
| Q2 2013 | +413,937 | Add 0.00% | 413,936 | $41.03 |
| Q3 2013 | -147,464 | Reduce 35.62% | 266,472 | $46.26 |
| Q4 2013 | +20,959 | Add 7.87% | 287,431 | $53.04 |
| Q1 2014 | +25,800 | Add 8.98% | 313,231 | $60.34 |
| Q2 2014 | +115,700 | Add 36.94% | 428,931 | $53.52 |
| Q3 2014 | -22,495 | Reduce 5.24% | 406,436 | $59.74 |
| Q4 2014 | +52,262 | Add 12.86% | 458,698 | $63.64 |
| Q1 2015 | -55,400 | Reduce 12.08% | 403,298 | $79.29 |
| Q2 2015 | +73,904 | Add 18.32% | 477,202 | $70.34 |
| Q3 2015 | +155,029 | Add 32.49% | 632,231 | $63.52 |
| Q4 2015 | +205,136 | Add 32.45% | 837,367 | $80.39 |
| Q1 2016 | +107,096 | Add 12.79% | 944,463 | $75.94 |
| Q2 2016 | +166,035 | Add 17.58% | 1.11 M | $82.44 |
| Q3 2016 | +41,022 | Add 3.69% | 1.15 M | $83.34 |
| Q4 2016 | -28,805 | Reduce 2.50% | 1.12 M | $76.19 |
| Q1 2017 | -17,620 | Reduce 1.57% | 1.11 M | $89.95 |
| Q2 2017 | +1,427 | Add 0.13% | 1.11 M | $101.15 |
| Q3 2017 | +405,859 | Add 36.68% | 1.51 M | $108.02 |
| Q4 2017 | +10,906 | Add 0.72% | 1.52 M | $109.45 |
| Q1 2018 | +4,578 | Add 0.30% | 1.53 M | $106.74 |
| Q2 2018 | +96,522 | Add 6.32% | 1.62 M | $112.26 |
| Q3 2018 | -4,828 | Reduce 0.30% | 1.62 M | $134.54 |
| Q4 2018 | +146,201 | Add 9.03% | 1.77 M | $113.18 |
| Q1 2019 | +317,001 | Add 17.95% | 2.08 M | $144.54 |
| Q2 2019 | +157,160 | Add 7.55% | 2.24 M | $141.90 |
| Q3 2019 | -232,993 | Reduce 10.40% | 2.01 M | $132.37 |
| Q4 2019 | -334,771 | Reduce 16.68% | 1.67 M | $152.75 |
| Q1 2020 | -316,752 | Reduce 18.94% | 1.36 M | $126.21 |
| Q2 2020 | -631,701 | Reduce 46.61% | 723,704 | $170.41 |
| Q3 2020 | -316,950 | Reduce 43.80% | 406,754 | $223.39 |
| Q4 2020 | -151,236 | Reduce 37.18% | 255,518 | $246.22 |
| Q1 2021 | -84,835 | Reduce 33.20% | 170,683 | $289.83 |
| Q2 2021 | -79,665 | Reduce 46.67% | 91,018 | $369.69 |
| Q3 2021 | -3,245 | Reduce 3.57% | 87,773 | $412.67 |
| Q4 2021 | -6,700 | Reduce 7.63% | 81,073 | $376.78 |
| Q1 2022 | +40,193 | Add 49.58% | 121,266 | $283.97 |
| Q2 2022 | +59,131 | Add 48.76% | 180,397 | $213.97 |
| Q3 2022 | -70,368 | Reduce 39.01% | 110,029 | $196.80 |
| Q4 2022 | -53,472 | Reduce 48.60% | 56,557 | $217.70 |
| Q1 2023 | +14,524 | Add 25.68% | 71,081 | $199.63 |
| Q2 2023 | -5,812 | Reduce 8.18% | 65,269 | $210.25 |
| Q3 2023 | +19,347 | Add 29.64% | 84,616 | $195.98 |
| Q4 2023 | -11,643 | Reduce 13.76% | 72,973 | $236.40 |
| Q1 2024 | -31,955 | Reduce 43.79% | 41,018 | $268.98 |
| Q2 2024 | +21,235 | Add 51.77% | 62,253 | $206.58 |
| Q3 2024 | -17,626 | Reduce 28.31% | 44,627 | $196.97 |
| Q4 2024 | -23,650 | Reduce 52.99% | 20,977 | $184.60 |
| Q1 2025 | -14,741 | Reduce 70.27% | 6,236 | $149.17 |
| Q2 2025 | +20,520 | Add 329.06% | 26,756 | $150.09 |
| Q3 2025 | +238,327 | Add 890.74% | 265,083 | $149.10 |
Cliff Asness's Charles River Laboratories International Investment FAQs
Cliff Asness first purchased Charles River Laboratories International, Inc. (CRL) in Q4 2012, acquiring 410,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Charles River Laboratories International, Inc. (CRL) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q2 2013, adding 413,936 shares worth $16.98 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 265,083 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $39.52 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 0.03% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Charles River Laboratories International, Inc. (CRL) was 2,239,921 shares, as reported at the end of Q2 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.